Establishment of Reference Values for Insulin-like Growth Factor 1 (IGF1) in the General Population

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

924 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-05-31

Study Completion Date

2012-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Various assays can be used for IGF-I measurement in French laboratories. Unfortunately, each assay gives a very different result for the same sample. As IGF-I also varies with age, it is necessary to establish a broad population reference values of IGF1 concentration for each of the IGF1 assays used in clinical practice, taking into account individual variation factors such as age, nutritional status and possible treatments.

The objective of this study is to establish normative data based on a large random selection from the general population, including representation from all age groups (around 100 subjects for each decade age range). This will be performed for all the available assay kits. Subjects with medical conditions and medications that may affect the outcome will be excluded. Normative data will include the range (2.5 to 97.5 percentiles) in mass units and results will be reported as mass units but also as SD scores in order to be able, in a given patient, to compare its IGF-I concentration along time, even if using different assays.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Macronutrients and Gut Hormone Secretion

NCT01366794

Type 2 Diabetes

COMPLETED NA

Diabetes and Metabolic Postprandial Responses

NCT00767208

Type 2 Diabetes Overweight

COMPLETED NA

Importance of the GH/IGF-1 Axis for Human Substrate and Energy Metabolism During Calorie Restriction

NCT01209429

Healthy

COMPLETED NA

Studies of the Early Meal Phase in Healthy Individuals - Nutrient Absorption and Gastrointestinal Hormone Secretion

NCT03543423

Healthy

UNKNOWN NA

Effects of Low Fat Versus Low Carbohydrate Diets on Energy Metabolism

NCT03878108

Healthy Healthy Volunteers

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Healthy subjects will be recruited in 30 centers all around France. A total of 1000 healthy subjects are necessary. Each subject will have a clinical examination with measurement of height and weight. Personal medical history will be recorded and gonadal status evaluated. Biological standard workup will be performed and 80 ml of blood will be sampled and serum will be aliquoted, frozen and stored at -80°C. IGF-I level will be measured with all the assay methods available (sera kept in bank will be used in the future when new methods will be available) For each assay method and each age group (Four 3-years groups between 18 and 30 years and six decade age groups between 30 and 89 years) IGF-I will be measured.

Results will be expressed as mean, median, standard deviation, 2.5th and 97.5th percentiles, in mass units. Modelisation according to age and other factors will be performed in order to allow the reporting of IGF-I results for a given individual expression of IGF-I as Z-score.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Population

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

HEALTH_SERVICES_RESEARCH

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Volonteers

Blood sample

Group Type EXPERIMENTAL

Blood sample

Intervention Type OTHER

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Blood sample

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or female 18 to 89 years old (18 years ≤ age ≤ 89 years)
* Consent given by the patient
* No history of : thyroid disease, liver disease or kidney disease or metabolic endocrine disease cardiovascular or pulmonary disease, neoplastic disease, gastroenterological disease (malabsorption, parasites, chronic diarrhea, peptic disease), psychiatric illness, epilepsy.
* No medication that can interfere with the concentration of IGF1: steroids, anti-androgens, distal diuretics, anti-estrogens, enzyme inducers (rifampin, rifabutin, phenobarbital, phenytoin, carbamazepine, herbal St. John's wort, efavirenz, nevirapine, griseofulvin , OP'DDD, mitotane).
* No intercurrent illness in the week preceding the inclusion
* No known chronic infectious disease (BVH, CVH, HIV)
* No active smoking
* Weight/height2 (BMI) less than 28 kg/m2 and greater than 19 kg/m2
* Normal clinical examination
* Normal blood pressure: children under 65 years (100 mm Hg \<SBP \<140 mmHg, 50 mmHg \<PAD \<90 mmHg) for over 65 years (100 mm Hg \<SBP \<150 mmHg, 50 mmHg \<SBP \<90mmHg )

Exclusion Criteria

* Uncontrolled intercurrent illness
* Pregnant or lactating woman
* Excess alcohol consumption: more than 50 g/24h of chronic or acute or unable to restraint from consuming alcohol
* Susceptible to use drugs
* Donated blood in the 3 months preceding the study
* Blood transfusion in the 3 months preceding the test
* Exclusion period of a previous experimental trial.
* Fasting extended by several days.
* Patient not affiliated to a social security system (is or should be beneficiary)

Minimum Eligible Age

18 Years

Maximum Eligible Age

89 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes